Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.
Pal S, Grivas P, Gupta S, Valderrama B, Rodriguez-Vida A, Roghmann F, Sevillano E, Matin S, Loriot Y, Sridhar S, Sonpavde G, Fleming M, Lerner S, Bellmunt J, Master V, Tripathi A, Davis K, Van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study. Journal Of Clinical Oncology 2024, 42: 629-629. DOI: 10.1200/jco.2024.42.4_suppl.629.Peer-Reviewed Original ResearchDisease-free survivalMetastasis-free survivalOverall survivalUrothelial cancerFibroblast growth factor 3FGFR3 alterationsAdjuvant therapyAdverse eventsInvestigator-assessed disease-free survivalMulticenter phase III clinical trialAssessed disease-free survivalPhase III clinical trialsLower tract UCUpper tract UCDays of randomizationFatal adverse eventsIII clinical trialsPrecision oncology trialsDFS analysisMetastatic settingOral infigratinibRadical surgeryDisease recurrenceFrequent gradeInvasive UC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply